[Edaily Reporter Kwon Oh Seok ] JAEYOUNG SOLUTEC CO.,LTD.(049630)’s stock price is surging in early trading. It appears that buying interest is surging on news that the company’s earnings improvement has significantly expanded. (Photo courtesy of JAEYOUNG SOLUTEC CO.,LTD.) According to MP Doctor on the 14th, as of 9:09 a.m., JAEYOUNG SOLUTEC CO.,LTD. is trading at 8,140 won, up 17.12% from the previous trading day. Previously, on the 13th, JAEYOUNG SOLUTEC CO.,LTD. announced that it recorded consolidated revenue of 107 billion won and operating profit of 17.1 billion won for the first half of this year. Revenue increased by 49% year-over-year, while operating profit surged by 5,800%. Net income stood at 15.8 billion won, marking a turnaround from a net loss of 3 billion won in the same period last year. Notably, first-half operating profit exceeded last year’s full-year operating profit of 10.7 billion won. The company explained that the expansion of production lines and automation efforts pursued over the past several years have led to improved profitability. Second-quarter revenue reached 49 billion won, a 47% increase year-over-year. Operating profit stood at 8 billion won, and net income at 6.5 billion won, with both figures turning to profit. The company explained that this improvement in performance is not a temporary result but rather the visible outcome of the 100 billion won in proactive investments made over the past five years. To strengthen its competitiveness in the actuator business, JAEYOUNG SOLUTEC CO.,LTD. has pursued the expansion of production lines and the introduction of automated robotic equipment, while continuously investing in the upgrading of its production hub in Vietnam. JAEYOUNG SOLUTEC CO.,LTD. official stated, “We will continue to further solidify our stable profit-generating structure and strive for sustained growth and enhanced corporate value based on our accumulated technological expertise and production capabilities.”
“Donghaeng,” a labor union composed primarily of employees from SamsungElectronics’ Device Experience (DX) Division, is holding a rally in front of Jay Y. Lee’s residence to demand the elimination of …
SK BIOPHARMACEUTICALS(326030)is attributing significance beyond that of a mere follow-up pipeline to Opakalim (BHV-7000), a new epilepsy drug candidate it acquired from the U.S.-based Biohaven. It is …
South Korea’s pharmaceutical and biotech sector experienced significant volatility on August 13, driven by growth themes in obesity/medical aesthetics, hair loss, and immuno-oncology. #GCWellbeing sur…